{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-076551","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2022-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.942621+00:00","generated_at":"2026-06-24T21:45:26.325138+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"HOOKIPA shareholders approve doubling authorized shares to 200M and reverse split range","bullets":["Authorized common shares increased from 100M to 200M via Certificate of Amendment.","Shareholders authorized reverse stock split in range of 1-for-2 to 1-for-10, if board elects.","Class III directors Julie O'Neill and Reinhard Kandera elected for three-year terms.","Stockholders ratified PwC Wirtschaftsprüfung GmbH as auditor for FY 2022.","2019 Stock Incentive Plan amended to increase authorized shares by 1M shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-076551","json":"https://secwatch.observer/filing/0001104659-22-076551.json","markdown":"https://secwatch.observer/filing/0001104659-22-076551.md","text":"https://secwatch.observer/filing/0001104659-22-076551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922076551/0001104659-22-076551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922076551/tm2220184d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T21:45:26.325138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}